A Study of TAF in Combination With PEG-IFN and Hepalatide in Subjects With Chronic Hepatitis B
Status:
Not yet recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
The study is designed to assess efficacy of hepalatide in Combination with Pegylated
Interferon and TAF compared to Pegylated Interferon in Combination with TAF in patients with
Chronic Hepatitis B .Subjects will be randomly assigned to the hepalatide or placebo groups ,
15 subjects in each group . Subjects will receive hepalatide+Pegylated Interferon +TAF
treatment for 48 weeks or placebo +Pegylated Interferon +TAF treatment for 48 weeks ,
followed by a safety follow-up for 24 weeks.